Clinical trial
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With…
NCT00279448 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00279448 |
|---|---|
| Title | Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer |
| Official title | Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+… |
| Acronym | TEAM |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | exemestane, tamoxifen |
| Enrollment | 9,779 |
| Start date | Jan 1, 2002 |
| Primary completion | Nov 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Jan 19, 2006 |
| Last update posted | Dec 23, 2011 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: